The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Genomic and immune signatures of ibrutinib response and resistance in Waldenström macroglobulinemia
Tina Bagratuni, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses distinct genomic and immune signatures associated with response and resistance to ibrutinib in Waldenström’s macroglobulinemia. She highlights gene expression signatures associated with progression-free survival, including a set of approximately 20 genes that may help predict ibrutinib response beyond MYD88 and CXCR4 mutation status, as well as immune exhaustion, regulatory T cells and inflammatory pathways that distinguish non-responders following treatment. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
